Top

Published in:

01-10-2016 | Original Article

A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer

Authors: Hong-Fei Zhang, Jie-Jie Qin, Peng-Fei Ren, Jian-Xiang Shi, Jun-Fen Xia, Hua Ye, Peng Wang, Chun-Hua Song, Kai-Juan Wang, Jian-Ying Zhang

Published in: Cancer Immunology, Immunotherapy | Issue 10/2016

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in China with very low 5-year survival rate mostly due to the paucity of effective early diagnostic methods. Serum autoantibodies against 9 tumor-associated antigens (TAAs) from ESCC patients and healthy controls were detected by enzyme-linked immunosorbent assay to evaluate their performances in the immunodiagnosis of ESCC. Logistic regression models were generated to predict the probability of individuals being diagnosed with ESCC in training cohort (648 participants) and further validated in another independent cohort (372 participants). Finally, a panel of four TAAs showed high diagnostic accuracy with areas under the receiver operating characteristic curve of 0.838 in training cohort and 0.872 in validation cohort, respectively. The percentages of individuals correctly classified were 77.01 % in training cohort and 78.49 % in validation cohort, respectively. This model could discriminate early-stage (AJCC stage 0, I and II) ESCC patients from normal controls, with true-positive rate (TPR) of 67.57 % in training cohort and TPR of 63.33 % in validation cohort, and the overall TPR for early-stage ESCC was 66.85 % when the two cohorts were combined. The diagnostic performance of this model showed no significant difference between early-stage and late-stage (AJCC stage III and IV) ESCC patients. In summary, the optimized model with 4 TAAs has a high diagnostic performance for ESCC detection, especially for early-stage ESCC.

Available only for authorised users

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. doi:10.1002/ijc.29210 CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108. doi:10.3322/caac.21262 CrossRefPubMed

Arnold M, Soerjomataram I, Ferlay J, Forman D (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64(3):381–387. doi:10.1136/gutjnl-2014-308124 CrossRefPubMed

Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG, Hur J, Chung H, Park JC, da Jung H, Shin SK, Lee SK, Lee YC, Kim HR, Moon YW, Kim JH, Shim YM, Jewell SS, Kim H, Choi YL, Cho BC (2015) Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget 6(4):2562–2572. doi:10.18632/oncotarget.2944 CrossRefPubMed

Zhao Y, Schetter AJ, Yang GB, Nguyen G, Mathe EA, Li P, Cai H, Yu L, Liu F, Hang D, Yang H, Wang XW, Ke Y, Harris CC (2013) microRNA and inflammatory gene expression as prognostic marker for overall survival in esophageal squamous cell carcinoma. Int J Cancer 132(12):2901–2909. doi:10.1002/ijc.27954 CrossRefPubMed

Wong GS, Habibollahi P, Heidari P, Lee JS, Klein-Szanto AJ, Waldron TJ, Gimotty P, Nakagawa H, Taylor PR, Wang TC, Mahmood U, Rustgi AK (2013) Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology 144(2):294–297. doi:10.1053/j.gastro.2012.10.030 CrossRefPubMed

Lin C, Song L, Gong H, Liu A, Lin X, Wu J, Li M, Li J (2013) Nk2–8 downregulation promotes angiogenesis and activates NF-kappaB in esophageal cancer. Cancer Res 73(12):3638–3648. doi:10.1158/0008-5472.CAN-12-4028 CrossRefPubMed

Song Y, Li L, Ou Y, Gao Z, Li E, Li X, Zhang W, Wang J, Xu L, Zhou Y, Ma X, Liu L, Zhao Z, Huang X, Fan J, Dong L, Chen G, Ma L, Yang J, Chen L, He M, Li M, Zhuang X, Huang K, Qiu K, Yin G, Guo G, Feng Q, Chen P, Wu Z, Wu J, Zhao J, Luo L, Fu M, Xu B, Chen B, Li Y, Tong T, Wang M, Liu Z, Lin D, Zhang X, Yang H, Zhan Q (2014) Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509(7498):91–95. doi:10.1038/nature13176 CrossRefPubMed

Huang ZL, Lin ZR, Xiao YR, Cao X, Zhu LC, Zeng MS, Zhong Q, Wen ZS (2015) High expression of TACC3 in esophageal squamous cell carcinoma correlates with poor prognosis. Oncotarget 6(9):6850–6861. doi:10.18632/oncotarget.3190 CrossRefPubMedPubMedCentral

10.

Hu YC, Lam KY, Law S, Wong J, Srivastava G (2001) Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7(11):3519–3525PubMed

11.

Zhang C, Wang C, Chen X, Yang C, Li K, Wang J, Dai J, Hu Z, Zhou X, Chen L, Zhang Y, Li Y, Qiu H, Xing J, Liang Z, Ren B, Zen K, Zhang CY (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56(12):1871–1879. doi:10.1373/clinchem.2010.147553 CrossRefPubMed

12.

Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, Morimura R, Tsujiura M, Nagata H, Kawaguchi T, Arita T, Kubota T, Fujiwara H, Okamoto K, Otsuji E (2013) Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 108(9):1822–1829. doi:10.1038/bjc.2013.148 CrossRefPubMedPubMedCentral

13.

Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, Xie HW, Lv J, Wu QQ, Cao XF (2015) Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer 14:3. doi:10.1186/1476-4598-14-3 CrossRefPubMedPubMedCentral

14.

Li B, Wang B, Niu LJ, Jiang L, Qiu CC (2011) Hypermethylation of multiple tumor-related genes associated with DNMT3b up-regulation served as a biomarker for early diagnosis of esophageal squamous cell carcinoma. Epigenetics 6(3):307–316CrossRefPubMedPubMedCentral

15.

Imai H, Nakano Y, Kiyosawa K, Tan EM (1993) Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 71(1):26–35CrossRefPubMed

16.

Chapman CJ, Thorpe AJ, Murray A, Parsy-Kowalska CB, Allen J, Stafford KM, Chauhan AS, Kite TA, Maddison P, Robertson JF (2011) Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 17(6):1474–1480. doi:10.1158/1078-0432.CCR-10-1363 CrossRefPubMed

17.

Pedersen JW, Gentry-Maharaj A, Nostdal A, Fourkala EO, Dawnay A, Burnell M, Zaikin A, Burchell J, Papadimitriou JT, Clausen H, Jacobs I, Menon U, Wandall HH (2014) Cancer-associated autoantibodies to MUC1 and MUC4–a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer 134(9):2180–2188. doi:10.1002/ijc.28538 CrossRefPubMed

18.

Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4(4):1123–1133. doi:10.1021/pr0500814 CrossRefPubMedPubMedCentral

19.

Zaenker P, Ziman MR (2013) Serologic autoantibodies as diagnostic cancer biomarkers–a review. Cancer Epidemiol Biomark Prev 22(12):2161–2181. doi:10.1158/1055-9965.EPI-13-0621 CrossRef

20.

Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomark Prev 12(2):136–143

21.

Tonisson N, Zernant J, Kurg A, Pavel H, Slavin G, Roomere H, Meiel A, Hainaut P, Metspalu A (2002) Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Nat Acad Sci USA 99(8):5503–5508. doi:10.1073/pnas.082100599 CrossRefPubMedPubMedCentral

22.

Bourdon JC (2007) p53 and its isoforms in cancer. Br J Cancer 97(3):277–282. doi:10.1038/sj.bjc.6603886 CrossRefPubMedPubMedCentral

23.

Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8(4):275–283. doi:10.1038/nrm2147 CrossRefPubMed

24.

Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R (2007) Non-transcriptional control of DNA replication by c-Myc. Nature 448(7152):445–451. doi:10.1038/nature05953 CrossRefPubMed

25.

Ko J, Lee YH, Hwang SY, Lee YS, Shin SM, Hwang JH, Kim J, Kim YW, Jang SW, Ryoo ZY, Kim IK, Namkoong SE, Kim JW (2003) Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization. Oncogene 22(30):4679–4689. doi:10.1038/sj.onc.1206624 CrossRefPubMed

26.

Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19(2):1262–1270CrossRefPubMedPubMedCentral

27.

Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J (2007) CIP2A inhibits PP2A in human malignancies. Cell 130(1):51–62. doi:10.1016/j.cell.2007.04.044 CrossRefPubMed

28.

Robertson KD, Jones PA (1999) Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 18(26):3810–3820. doi:10.1038/sj.onc.1202737 CrossRefPubMed

29.

Koff A, Cross F, Fisher A, Schumacher J, Leguellec K, Philippe M, Roberts JM (1991) Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 66(6):1217–1228CrossRefPubMed

30.

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed

31.

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J (2011) Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol: Off J Am Soci Clin Oncol 29(36):4781–4788. doi:10.1200/JCO.2011.38.2697 CrossRef

32.

Wu L, Qu X (2015) Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev 44(10):2963–2997. doi:10.1039/c4cs00370e CrossRefPubMed

33.

Harada T, Kuramitsu Y, Makino A, Fujimoto M, Iizuka N, Hoshii Y, Takashima M, Tamesa M, Nishimura T, Takeda S, Abe T, Yoshino S, Oka M, Nakamura K (2007) Expression of tropomyosin alpha 4 chain is increased in esophageal squamous cell carcinoma as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Proteomics Clin Appl 1(2):215–223. doi:10.1002/prca.200600609 CrossRefPubMed

34.

Motoyama S, Miura M, Hinai Y, Maruyama K, Usami S, Nakatsu T, Saito H, Minamiya Y, Suzuki T, Ogawa J (2009) C-reactive protein 1059G>C genetic polymorphism influences serum C-reactive protein levels after esophagectomy in patients with thoracic esophageal cancer. J Am Coll Surg 209(4):477–483. doi:10.1016/j.jamcollsurg.2009.06.365 CrossRefPubMed

35.

Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Szmitkowski M (2012) Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients. Dis Esophagus 25(3):242–249. doi:10.1111/j.1442-2050.2011.01242.x CrossRefPubMed

36.

Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ (2000) CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res 6(11):4249–4252PubMed

37.

Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18(5):868–873. doi:10.1093/annonc/mdm007 CrossRefPubMed

38.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353(12):1224–1235. doi:10.1056/NEJMoa051931 CrossRefPubMed

39.

Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF (2008) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63(3):228–233. doi:10.1136/thx.2007.083592 CrossRefPubMed

40.

Zhu Q, Han SX, Zhou CY, Cai MJ, Dai LP, Zhang JY (2015) Autoimmune response to PARP and BRCA1/BRCA2 in cancer. Oncotarget 6(13):11575–11584. doi:10.18632/oncotarget.3428 CrossRefPubMedPubMedCentral

41.

Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li B, Han XN, Ku JW, Zhao XK, Zhang P, Cui J, Zhou FY, Zhang LQ, Fan XP, Zhou YF, Zhu LL, Liu HY, Wang LD (2014) Autoantibody detection to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62, C-myc, Survivn, and Koc for the screening of high-risk subjects and early detection of esophageal squamous cell carcinoma. Dis Esophagus 27(8):790–797. doi:10.1111/dote.12145 CrossRefPubMed

42.

Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH, Zheng CP, Wang SH, Guo HP, Li EM, Xu LY (2014) Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol 109(1):36–45. doi:10.1038/ajg.2013.384 CrossRefPubMed

43.

Werner S, Chen H, Tao S, Brenner H (2015) Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer 136(10):2243–2252. doi:10.1002/ijc.28807 CrossRefPubMed

44.

Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Nat Cancer Inst 93(14):1054–1061CrossRefPubMed

Title: A panel of autoantibodies against multiple tumor-associated antigens in the immunodiagnosis of esophageal squamous cell cancer
Authors: Hong-Fei Zhang
Jie-Jie Qin
Peng-Fei Ren
Jian-Xiang Shi
Jun-Fen Xia
Hua Ye
Peng Wang
Chun-Hua Song
Kai-Juan Wang
Jian-Ying Zhang
Publication date: 01-10-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 10/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1886-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer

Concepts in glioma immunotherapy

Opportunities for immunotherapy in microsatellite instable colorectal cancer

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer